News & Updates
Filter by Specialty:
NATALEE update: Ribociclib + NSAI well tolerated
Latest findings from the ongoing phase III NATALEE trial have shown that 3-year treatment with adjuvant ribociclib, in combination with a nonsteroidal aromatase inhibitor (NSAI), remained well tolerated in patients with HR+/HER2- early-stage breast cancer (EBC).
NATALEE update: Ribociclib + NSAI well tolerated
12 Jul 2024
Poor glycaemic control ups risk of stent failure in T2D patients
Poor glycaemic control appears to contribute to coronary stent failure driven by in-stent restenosis in patients with type 2 diabetes (T2D), suggests a study.
Poor glycaemic control ups risk of stent failure in T2D patients
12 Jul 2024
Low-fat vegan diet a game-changer for T1D?
New research has shown that a low-fat vegan diet rich in vegetables, fruits, whole grains, and legumes can improve insulin sensitivity in adult patients with type 1 diabetes (T1D), thus reducing their daily insulin requirements. The finding may fuel the momentum for dietary shifts in this population.
Low-fat vegan diet a game-changer for T1D?
12 Jul 2024
Real-world data support DOACs over warfarin for VTE
The direct oral anticoagulants (DOACs) apixaban and rivaroxaban trump warfarin for the treatment of venous thromboembolism (VTE) in a retrospective observational analysis comprising real-world VTE patients from Finland, Norway, and Sweden.
Real-world data support DOACs over warfarin for VTE
12 Jul 2024
DESTINY-Breast03 reports longest OS in previously treated HER2-positive mBC
Long-term follow-up of the DESTINY-Breast03 trial has reported a median overall survival (OS) of 52.6 months with trastuzumab deruxtecan (T-DXd), representing the longest reported OS in previously treated HER2-positive metastatic breast cancer (mBC) to date.
